Literature DB >> 19125908

Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models.

K-Y Seng1, C-Y Fun, Y-L Law, W-M Lim, W Fan, C-L Lim.   

Abstract

OBJECTIVE: Caffeine has been shown to maintain or improve the performance of individuals, but its pharmacokinetic profile for Asians has not been well characterized. In this study, a population pharmacokinetic model for describing the pharmacokinetics of caffeine in Singapore males was developed. The data were also analysed using non-compartmental models.
METHODS: Data gathered from 59 male volunteers, who each ingested a single caffeine capsule in two clinical trials (3 or 5 mg/kg), were analysed via non-linear mixed-effects modelling. The participants' covariates, including age, body weight, and regularity of caffeinated-beverage consumption or smoking, were analysed in a stepwise fashion to identify their potential influence on caffeine pharmacokinetics. The final pharmacostatistical model was then subjected to stochastic simulation to predict the plasma concentrations of caffeine after oral (204, 340 and 476 mg) dosing regimens (repeated dosing every 6, 8 or 12 h) over a hypothetical 3-day period.
RESULTS: The data were best described by a one-compartmental model with first-order absorption and first-order elimination. Smoking status was an influential covariate for clearance: clearance (mL/min) = 110*SMOKE + 114, where SMOKE was 0 and 1 for the non-smoker and the smoker respectively. Interoccasion variability was smaller compared to interindividual variability in clearance, volume and absorption rate (27% vs. 33%, 10% vs. 15% and 23% vs. 51% respectively). The extrapolated elimination half-lives of caffeine in the non-smokers and the smokers were 4.3 +/- 1.5 and 3.0 +/- 0.7 h respectively. Dosing simulations indicated that dosing regimens of 340 mg (repeated every 8 h) and 476 mg (repeated every 6 h) should achieve population-averaged caffeine concentrations within the reported beneficial range (4.5-9 microg/mL) in the non-smokers and the smokers respectively over 72 h.
CONCLUSION: The population pharmacokinetic model satisfactorily described the disposition and variability of caffeine in the data. Mixed-effects modelling showed that the dose of caffeine depended on cigarette smoking status.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19125908     DOI: 10.1111/j.1365-2710.2008.00976.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  5 in total

1.  A Preliminary Study on the Effects of Self-Reported Dietary Caffeine on Pain Experience and Postoperative Analgesia.

Authors:  Nirmani P Karunathilake; Reginald F Frye; Mary F Stavropoulos; Mary A Herman; Barbara A Hastie
Journal:  J Caffeine Res       Date:  2012-12

2.  Normalized diurnal and between-day trends in illicit and legal drug loads that account for changes in population.

Authors:  Alex J Brewer; Christoph Ort; Caleb J Banta-Green; Jean-Daniel Berset; Jennifer A Field
Journal:  Environ Sci Technol       Date:  2012-07-17       Impact factor: 9.028

3.  PK-DB: pharmacokinetics database for individualized and stratified computational modeling.

Authors:  Jan Grzegorzewski; Janosch Brandhorst; Kathleen Green; Dimitra Eleftheriadou; Yannick Duport; Florian Barthorscht; Adrian Köller; Danny Yu Jia Ke; Sara De Angelis; Matthias König
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

Review 4.  Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing.

Authors:  Jan Grzegorzewski; Florian Bartsch; Adrian Köller; Matthias König
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

5.  Duration of Analgesia Induced by Acupuncture-Like TENS on Experimental Heat Pain.

Authors:  Yannick Tousignant-Laflamme; Marilyne Brochu; Cynthia Dupuis-Michaud; Catherine Pagé; Draga Popovic; Marie-Eve Simard
Journal:  ISRN Pain       Date:  2013-04-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.